Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
BioArctic AB (BRCTF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of BioArctic AB $48.15, price $36.92, upside +30.4%, quality 85 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
BA
Broad data
Sep 24, 2026
Broad data
Sep 24, 2026
BioArctic AB
BRCTF · USUndervalued, solidFair Value upside is positive and quality is strong.
✓Fair value $48.15 · Undervalued (+30.4%)
✓Quality 85/100
!Mixed Growth (revenue 5y +100.0 %/yr)
✓Solidly profitable · 18.6% net margin (TTM)
✓generates free cash flow
✓Wide moat 71/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
46‑month range $12.95 – $38.75 · fair‑value band $27.06 – $83.78 · the $36.92 price screens below the $48.15 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs.
Show more
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment. Further, it is developing Lecanemab for Subcutaneous treatment, which is in registration stage; lecanemab, which is in phase 3 clinical trials for presymptomatic treatment; Exidavnemab, which is in phase 2 clinical trials; Lecanemab back-up, BAN2803, ND3014, and BAN2802 that are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, PD-BT2238 which are in research stage. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Stock analysis
BioArctic AB (BRCTF) currently trades at $36.92, while our model-based Fair Value estimate is $48.15, implying the stock looks roughly 23.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $63.48 per share, and 11 of the 23 models we run sit above the $36.92 price.
Bear case: the Multiples group reads lowest at $11.83, and 12 of the 23 models stay below the price. Evidence for this calculation is high.
Scenario range: $27.06 (bear) to $83.78 (bull), the price of $36.92 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 85/100 (high quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BioArctic AB reported revenue of 2.0B SEK in FY2025 versus 23.1M SEK in FY2021, a compound +204.7%/yr. Reported net income was 1.0B SEK in FY2025.
Key figures
Market cap $3.3B · P/E ratio 140.0 · P/S ratio 71.6 · EPS (TTM) $0.2500 · Net margin 51.1% · Return on equity 10.3% · Return on assets (EBIT) 7.3% · Revenue (TTM) 1.9B SEK.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).
What moves the price
The share trades about 5% below its 52-week high and 33% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 30%, BRCTF screens cheaper than that median.
Fair Value models
Bear $27.06
Fair Value $48.15
Bull $83.78
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.1890 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$32.34
$49.04
$101.10
72
EPV
$15.18
$17.36
$19.23
70
Growth DCF
$30.45
$56.71
$99.00
70
All 23 models by family
DCF Models
FCF DCF
$32.34
$49.04
$101.10
72
Owner Earnings
$22.35
$47.85
$99.40
66
5Y Revenue Exit
$14.67
$20.78
$33.25
67
5Y EBITDA Exit
$24.54
$40.73
$72.41
67
5Y P/E Exit
$26.88
$56.23
$95.87
63
10Y Revenue Exit
$19.96
$33.79
$40.00
63
10Y EBITDA Exit
$27.24
$54.56
$100.79
60
10Y P/E Exit
$28.91
$59.47
$108.86
56
Earnings-Based
Graham-Dodd
$9.29
$64.79
$90.92
61
Lynch FV
$33.47
$47.82
$62.16
59
PEG = 1.0
$33.47
$47.82
$62.16
55
EPV
$15.18
$17.36
$19.23
70
Multiples
P/E Multiple
$22.54
$30.06
$37.57
63
P/S Multiple
$7.01
$9.35
$11.69
58
P/B Multiple
$8.87
$11.83
$14.79
55
EV/EBIT
$24.70
$32.47
$40.24
63
EV/EBITDA
$20.77
$27.23
$33.69
64
EV/Revenue
$7.00
$9.41
$11.81
52
Asset-Based
NCAV (Graham)
$1.31
$1.76
$2.63
51
Growth DCF
Growth DCF
$30.45
$56.71
$99.00
70
Economic Profit
Residual Income
$8.62
$15.23
$45.77
56
ROIC Compounder
$16.79
$21.51
$26.92
68
Growth Earnings
Growth-Adj P/E
$44.43
$63.48
$82.52
65
Notify me when BRCTF reaches fair value
Put BRCTF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
85/100
Of which business quality 86 · Market factors (momentum, volatility) 62
Profitability
91
Margins and returns on capital today
Quality Growth
100
Are margins and returns improving?
Cashflow
90
Earnings quality: real cash, not paper profit
Fin. Strength
100
Balance sheet, leverage, solvency risk
Investment
33
Disciplined investing over empire-building
Low Volatility
59
Calm price path (market factor)
Momentum
50
Price trend over the last 3–12 months (market factor)
52W Momentum
88
Distance to the 52-week high (market factor)
Net Issuance
78
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
87/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+674.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+105.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+100.0%
Start year 2020 (pandemic). Over 10 years: +47.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.3%
’15
’16
’17
’18
’19
’20
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+62.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+62.8%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.62.8% vs 41.5%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−136% → 68%
Start year 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+14.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in SEK, Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +8.9% a year for the price and +11.8% for the forecasts.
Forecast 2026 (sales)−36.1%
Forecast 2027 (sales)+38.7%
Projected 2028 (sales)+34.1%
Projected 2029 (sales)+29.5%
Projected 2030 (sales)+25.0%
Watch BRCTF, get fair value alerts →
Compare BioArctic AB with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is BioArctic AB (BRCTF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $48.15 versus the last price from Sep 25, 2026 of $36.92, about +30% upside (undervalued).
What is the fair value of BRCTF?
Our model-based fair value for BioArctic AB is $48.15 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $36.92.
What is the quality score of BRCTF?
BioArctic AB has a Quality Score of 85/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioArctic AB (BRCTF)?
Our model-based price target is the fair value of $48.15 (as of Sep 24, 2026) from 23 valuation models. Cautious scenario $27.06, optimistic scenario $83.78. It is a calculation from audited fundamentals, not an analyst target.
What is the BioArctic AB stock forecast for 2026?
Our models put fair value at $48.15, about +30% upside versus the last price from Sep 25, 2026 of $36.92 (undervalued). Cautious scenario $27.06, optimistic scenario $83.78. The calculation is refreshed regularly with new filings.
What is the revenue of BioArctic AB (BRCTF)?
BioArctic AB reported trailing-twelve-month revenue of about 1.9B SEK (latest available figure, as of Sep 24, 2026).
What growth is priced into BioArctic AB (BRCTF)?
For today's price to be fair in a discounted-cash-flow model, BioArctic AB would have to grow free cash flow by +11.0 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +100.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of BRCTF use?
Our models discount BioArctic AB at 9.7 %: a base by market capitalisation (mid), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BioArctic AB that is +11.0 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has BioArctic AB (BRCTF) delivered so far?
Over the past 5 years revenue at BioArctic AB grew +100.0 % a year. The price currently implies +11.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BioArctic AB (BRCTF) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into BioArctic AB (+11.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BioArctic AB (BRCTF)?
The free-cash-flow yield on the price is 4.32 %: that much free cash flow BioArctic AB produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BioArctic AB (BRCTF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioArctic AB it is $48.15 per share (as of Sep 24, 2026), against a price of $36.92. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is BioArctic AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, BRCTF trades below its calculated fair value: price $36.92, fair value $48.15, a gap of about +30% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BRCTF?
No. The price is what the market pays today ($36.92); the fair value is what the company's own numbers justify ($48.15). For BioArctic AB the two are $11.23 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioArctic AB worth?
The market values BioArctic AB at about $3.3B (market capitalisation, as of Sep 24, 2026). Per share that is $36.92; our models calculate a fair value of $48.15 per share.
What do the bullish and bearish scenarios say about BRCTF?
Our models span a range for BioArctic AB: cautious scenario $27.06, base $48.15, optimistic $83.78 per share (as of Sep 24, 2026, price $36.92). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is BRCTF from its 52-week high?
BioArctic AB trades at $36.92, about 5% below its 52-week high of $38.75 and 33% above the low of $27.67 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $48.15 is for.
Which stocks are comparable to BioArctic AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioArctic AB stock attractive at the current price?
The data as of Sep 24, 2026: price $36.92, calculated fair value $48.15 (+30%), Quality Score 85/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BRCTF calculated?
We run BioArctic AB through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $48.15, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. BioArctic AB currently trades 23 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioArctic AB (BRCTF)?
The latest price we hold is from Sep 25, 2026 and stands at $36.92. Our model-based fair value is $48.15, about +30% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioArctic AB right now?
The rarer combination: high quality (85/100) AND below fair value. That earns a closer look rather than a quick verdict. The model range is unusually wide ($27.06 to $83.78). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Where does the earnings growth of BioArctic AB (BRCTF) come from?
Earnings per share at BioArctic AB grew +39.9 % a year from 2015 to 2025. Broken into its drivers: revenue per share +37.6 %, EBIT margin +1.6 %, tax rate +0.6 %, residual (interest, one-offs) −0.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of BioArctic AB
How large is the market capitalisation of BioArctic AB (BRCTF)?
The market capitalisation of BioArctic AB is $3.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of BioArctic AB (BRCTF)?
The price-to-earnings ratio of BioArctic AB is 140.0 (as of Jun 19, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of BioArctic AB (BRCTF)?
The price-to-sales ratio of BioArctic AB is 71.6 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioArctic AB (BRCTF)?
Earnings per share at BioArctic AB are $0.2500 (price ÷ EPS = P/E 140.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BioArctic AB (BRCTF)?
The net margin of BioArctic AB is 51.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioArctic AB (BRCTF)?
The return on equity (ROE) of BioArctic AB is 10.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioArctic AB (BRCTF)?
On an EBIT basis the return on assets of BioArctic AB is 7.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at BioArctic AB (BRCTF)?
Revenue at BioArctic AB is growing −66.1% versus a year earlier (3y avg +106%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioArctic AB (BRCTF)?
Earnings per share at BioArctic AB are growing −79.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does BioArctic AB (BRCTF) hold?
BioArctic AB holds more cash than debt, 994M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.